Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TWTR Twitter: Recent Pullback Creates Opportunity But Reducing PT, Says Topeka http://www.smarteranalyst.com/2014/10/28/twitter-recent-pullback-creates-opportunity-reducing-pt-says-topeka/
$TWTR Twitter: Recent Pullback Creates Opportunity But Reducing PT, Says Topeka http://www.smarteranalyst.com/2014/10/28/twitter-recent-pullback-creates-opportunity-reducing-pt-says-topeka/
$F Ford: Concerns Are Legitimate But Free Cash Flow Defendable, Says Deutsche Bank; Reduces PT To $16 http://www.smarteranalyst.com/2014/10/27/ford-concerns-legitimate-free-cash-flow-defendable-says-deutsche-bank-reduces-pt-16/
$VSLR Deutsche Bank Sees 45% Upside In Vivint Solar http://www.smarteranalyst.com/2014/10/27/deutsche-bank-sees-45-upside-vivint-solar/
$AEZS H.C. Wainwright Maintains Buy On Aeterna Zentaris Ahead Of FDA Ruling http://www.smarteranalyst.com/2014/10/27/h-c-wainwright-maintains-buy-aeterna-zentaris-ahead-fda-ruling/
$LGND Ligand Pharmaceuticals: Carbella CRL Delay No Big Deal Due To Diversified Revenues, Says Roth Capital http://www.smarteranalyst.com/2014/10/27/ligand-pharmaceuticals-carbella-crl-delay-big-deal-due-diversified-revenues-says-roth-capital/
$FB Cantor Maintains Buy On Facebook Ahead Of 3Q Results http://www.smarteranalyst.com/2014/10/27/cantor-maintains-buy-facebook-ahead-3q-results/
$FB Cantor Maintains Buy On Facebook Ahead Of 3Q Results http://www.smarteranalyst.com/2014/10/27/cantor-maintains-buy-facebook-ahead-3q-results/
$LNKD Cantor Sets Expectations On LinkedIn Ahead Of 3Q14 Earnings http://www.smarteranalyst.com/2014/10/27/cantor-sets-expectations-linkedin-ahead-3q14-earnings/
$GOGO William Blair Reaffirms Outperform On Gogo On The Heels Of A New Deal With United Airlines http://www.smarteranalyst.com/2014/10/15/william-blair-reaffirms-outperform-gogo-heels-new-deal-united-airlines/
$GOGO William Blair Reaffirms Outperform On Gogo On The Heels Of A New Deal With United Airlines http://www.smarteranalyst.com/2014/10/15/william-blair-reaffirms-outperform-gogo-heels-new-deal-united-airlines/
$PACB William Blair Maintains Market Perform Ahead Of Third-Quarter Earnings http://www.smarteranalyst.com/2014/10/15/william-blair-maintains-market-perform-ahead-third-quarter-earnings/
$GOOG Deutsche Bank Sets Expectations On Google Into 3Q14 Results; Reiterates Buy http://www.smarteranalyst.com/2014/10/15/deutsche-bank-sets-expectations-google-3q14-results-reiterates-buy/
$GOOG Deutsche Bank Sets Expectations On Google Into 3Q14 Results; Reiterates Buy http://www.smarteranalyst.com/2014/10/15/deutsche-bank-sets-expectations-google-3q14-results-reiterates-buy/
$INTC Deutsche Bank Maintains Bullish Stance On Intel Shares In Light Of 3Q14 Earnings http://www.smarteranalyst.com/2014/10/15/deutsche-bank-maintains-bullish-stance-intel-shares-light-3q14-earnings/
$INTC Deutsche Bank Maintains Bullish Stance On Intel Shares In Light Of 3Q14 Earnings http://www.smarteranalyst.com/2014/10/15/deutsche-bank-maintains-bullish-stance-intel-shares-light-3q14-earnings/
$FB We Would Add To FB Positions Heading Into 3Q Results, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/15/add-fb-positions-heading-3q-results-says-deutsche-bank/
$FB We Would Add To FB Positions Heading Into 3Q Results, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/15/add-fb-positions-heading-3q-results-says-deutsche-bank/
$AMZN We Continue To View AMZN As The Best Name In Western Markets E-Commerce, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/15/continue-view-amzn-best-name-western-markets-e-commerce-says-deutsche-bank/
$CLF Cliffs Natural Resources: The Risk/Reward Is Balanced At Today’s Valuation Level, Says Axiom http://www.smarteranalyst.com/2014/10/15/cliffs-natural-resources-riskreward-balanced-todays-valuation-level-says-axiom/
$CLF Cliffs Natural Resources: The Risk/Reward Is Balanced At Today’s Valuation Level, Says Axiom http://www.smarteranalyst.com/2014/10/15/cliffs-natural-resources-riskreward-balanced-todays-valuation-level-says-axiom/
$GALE Maxim Group Maintains Buy On Galena As It Strengthens Patent Portfolio With A New Japanese Patent http://www.smarteranalyst.com/2014/10/15/maxim-group-maintains-buy-galena-strengthens-patent-portfolio-new-japanese-patent/
$DRTX Durata Therapeutics: Moving To Neutral On Likely Closure Of Actavis Takeout, Says Roth Capital http://www.smarteranalyst.com/2014/10/15/durata-therapeutics-moving-neutral-likely-closure-actavis-takeout-says-roth-capital/
$DRTX Durata Therapeutics: Moving To Neutral On Likely Closure Of Actavis Takeout, Says Roth Capital http://www.smarteranalyst.com/2014/10/15/durata-therapeutics-moving-neutral-likely-closure-actavis-takeout-says-roth-capital/
$INTC Roth Capital Maintains Buy On Intel On The Back Of Good 3Q14 Results And Guidance http://www.smarteranalyst.com/2014/10/15/roth-capital-maintains-buy-intel-back-good-3q14-results-guidance/
$INTC Roth Capital Maintains Buy On Intel On The Back Of Good 3Q14 Results And Guidance http://www.smarteranalyst.com/2014/10/15/roth-capital-maintains-buy-intel-back-good-3q14-results-guidance/
$WFC Wells Fargo Quarterly Update; Oppenheimer Reiterates Perform http://www.smarteranalyst.com/2014/10/15/wells-fargo-quarterly-update-oppenheimer-reiterates-perform/
$FB Oppenheimer Reiterates Outperform On Facebook Ahead Of Earnings http://www.smarteranalyst.com/2014/10/15/oppenheimer-reiterates-outperform-facebook-ahead-earnings/
$FB Oppenheimer Reiterates Outperform On Facebook Ahead Of Earnings http://www.smarteranalyst.com/2014/10/15/oppenheimer-reiterates-outperform-facebook-ahead-earnings/
$INTC Oppenheimer Remains Perform On Intel As It Kicked Off Semiconductor Earnings Season http://www.smarteranalyst.com/2014/10/15/oppenheimer-remains-perform-intel-kicked-semiconductor-earnings-season/
$INTC Oppenheimer Remains Perform On Intel As It Kicked Off Semiconductor Earnings Season http://www.smarteranalyst.com/2014/10/15/oppenheimer-remains-perform-intel-kicked-semiconductor-earnings-season/
$JPM Oppenheimer Reiterates Outperform On JP Morgan Following 3Q14 Earnings http://www.smarteranalyst.com/2014/10/15/oppenheimer-reiterates-outperform-jp-morgan-following-3q14-earnings/
$JPM Oppenheimer Reiterates Outperform On JP Morgan Following 3Q14 Earnings http://www.smarteranalyst.com/2014/10/15/oppenheimer-reiterates-outperform-jp-morgan-following-3q14-earnings/
$GILD Harvoni Approval Solidifies Our View Of Gilead’s Market Leadership in HCV, Says William Blair http://www.smarteranalyst.com/2014/10/14/harvoni-approval-solidifies-view-gileads-market-leadership-hcv-says-william-blair/
$GILD Harvoni Approval Solidifies Our View Of Gilead’s Market Leadership in HCV, Says William Blair http://www.smarteranalyst.com/2014/10/14/harvoni-approval-solidifies-view-gileads-market-leadership-hcv-says-william-blair/
$IDRA Cowen Reiterates Outperform On Idera Following Initiation Of IMO-9200 Clinical Development http://www.smarteranalyst.com/2014/10/14/cowen-reiterates-outperform-on-idera-following-initiation-of-imo-9200-clinical-development/
$AVNR Cowen Maintains Bullish Stance On Avanir Pharmaceuticals; Raises PT To $20 http://www.smarteranalyst.com/2014/10/14/cowen-maintains-bullish-stance-avanir-pharmaceuticals-raises-pt-20/
$AVNR Cowen Maintains Bullish Stance On Avanir Pharmaceuticals; Raises PT To $20 http://www.smarteranalyst.com/2014/10/14/cowen-maintains-bullish-stance-avanir-pharmaceuticals-raises-pt-20/
$GWPH GW Pharmaceuticals Is Undervalued Based On The Potential Of Epidiolex And Sativex, Says Cowen http://www.smarteranalyst.com/2014/10/14/gw-pharmaceuticals-undervalued-based-potential-epidiolex-sativex-says-cowen/
$GWPH GW Pharmaceuticals Is Undervalued Based On The Potential Of Epidiolex And Sativex, Says Cowen http://www.smarteranalyst.com/2014/10/14/gw-pharmaceuticals-undervalued-based-potential-epidiolex-sativex-says-cowen/